Improvement of chronic facial pain and facial dyskinesia with the help of botulinum toxin application

Junghans, Katharina; Rohrbach, Saskia; Ellies, Maik; Laskawi, R.

doi:10.1186/1746-160x-3-32

Cited by 7 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An important, increasing field of application is the use of BTA in different pain syndromes , especially in patients suffering from tension headache, migraine and chronic daily headache (for review see [ 14 , 15 ]).…”

Section: Reviewmentioning

confidence: 99%

The use of botulinum toxin in head and face medicine: An interdisciplinary field

Laskawi

2008

Head Face Med

Self Cite

View full text Add to dashboard Cite

BackgroundIn this review article different interdisciplinary relevant applications of botulinum toxin type A (BTA) in the head and face region are demonstrated.Patients with head and face disorders of different etiology often suffer from disorders concerning their musculature (example: synkinesis in mimic muscles) or gland-secretion.This leads to many problems and reduces their quality of life. The application of BTA can improve movement disorders like blepharospasm, hemifacial spasm, synkinesis following defective healing of the facial nerve, palatal tremor, severe bruxism, oromandibular dystonias hypertrophy of the masseter muscle and disorders of the autonomous nerve system like hypersalivation, hyperlacrimation, pathological sweating and intrinsic rhinitis.ConclusionThe application of botulinum toxin type A is a helpful and minimally invasive treatment option to improve the quality of life in patients with head and face disorders of different quality and etiology. Side effects are rare.

show abstract

Section: Reviewmentioning

confidence: 99%

The use of botulinum toxin in head and face medicine: An interdisciplinary field

Laskawi

2008

Head Face Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…Analgesic effect following BT injections in orofacial pain are due to direct analgesic and neuromodulating mechanisms of BT in the central nervous system, anti-inflammatory effects, and effects on the myofascial tender point. [ 48 ] The underlying mechanism of a chronic pain syndrome is that the disease of the trigeminal nerve causes increased firing as well as impaired the efficiency of the inhibitory mechanisms that control afferent activity in the trigeminal nucleus. The increased neuronal activity in the afferent nociceptive neurons results in the perception of pain.…”

Section: Applicationsmentioning

confidence: 99%

Botulinum toxin: The Midas touch

Shilpa¹,

Kaul²,

Sultana³

et al. 2014

J Nat Sc Biol Med

View full text Add to dashboard Cite

Botulinum Toxin (BT) is a natural molecule produced during growth and autolysis of bacterium called Clostridium botulinum. Use of BT for cosmetic purposes has gained popularity over past two decades, and recently, other therapeutic uses of BT has been extensively studied. BT is considered as a minimally invasive agent that can be used in the treatment of various orofacial disorders and improving the quality of life in such patients. The objective of this article is to review the nature, mechanism of action of BT, and its application in various head and neck diseases.

show abstract

“…BTX inhibits substance P and is used in relieving excruciating pain associated with inflammation of trigeminal nerve, as it is an anti-inflammatory agent. Analgesic effect following BTX injections in orofacial pain are due to direct analgesic and neuromodulating mechanisms of BTX in the CNS, anti-inflammatory effects, and effects on the myofascial tender point [116]. Botox is also very useful in treating chronic pain syndrome [117].…”

Section: Salivary Secretory Disordersmentioning

confidence: 99%

The Emerging Role of Botulinum Toxin in the Treatment of Orofacial Disorders: Literature Update

Kumar

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Botulinum toxin (BTX) is a lethal neurotoxin produced by Gram-positive anaerobic bacterium called Clostridium botulinum. It is the first toxin used for therapeutic purposes since 1989. BTX treatment is relatively safe and efficacious, less invasive, conservative, and the effects are faster and reversible. The purpose of this article is to review the literature regarding the applications of BTX in the treatment of various orofacial disorders, their mechanism of action, contraindications, and complications. From the recently published literature, it is clear that the role of BTX as a therapeutic agent for several conditions is expanding. With the training of BTX-A injection techniques and adequate knowledge about treatment protocols, general dentists can safely administer BTX injections. The ability to use Botox as an adjuvant and primary mode of the treatment for various maxillofacial disorders offers exciting treatment options for dentists and patients in the future.

show abstract

Improvement of chronic facial pain and facial dyskinesia with the help of botulinum toxin application

Cited by 7 publications

References 22 publications

The use of botulinum toxin in head and face medicine: An interdisciplinary field

The use of botulinum toxin in head and face medicine: An interdisciplinary field

Botulinum toxin: The Midas touch

The Emerging Role of Botulinum Toxin in the Treatment of Orofacial Disorders: Literature Update

Contact Info

Product

Resources

About